[Thrombolytic effect of urokinase upon various methods of administration into the body].
A preparation of urokinase, obtained from human kidney cell culture, was administered into rats at a single dose of 5,000-10,000 U/200 g of body mass in a variety of ways using intravenous, intraperitoneal and subcutaneous inoculations. After intraperitoneal and subcutaneous administrations an increase of fibrinolytic activity in blood was more long-term although less distinct; the phase of reactive hypercoagulation was only slightly detected within 24 hrs after these procedures. Thrombin-produced provocation of thrombosis led to a lesser ratio of death in these animals as compared with the animals group administered intravenously. However, thrombolytic effect of similar doses of urokinase was the highest in intravenous administration. The fibrinolytic activity correlated well with content of the antigen (enzyme) in blood but not with the antiplasmin content in all the procedures used.
Andreenko
G V
GV
Serebriakova
T N
TN
Podorol'skaia
L V
LV
Afanasenko
G A
GA
Liaginskiĭ
A V
AV
Raevskaia
A K
AK
D000818:Animals; D002478:Cells, Cultured; D005342:Fibrinolysis / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D007263:Infusions, Parenteral; D007279:Injections, Subcutaneous; D051379:Mice; D013927:Thrombosis / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
D014568:Urokinase-Type Plasminogen Activator
Tromboliticheskoe deĭstvie urokinazy pri raznykh sposobakh ee vvedeniia v organizm.